



RECEIVED

DEC 10 2002

TECH CENTER 1600/2900

Sheet 1 of 2

FORM PTO-1449		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: DX01341		SERIAL NO.: 10/008,566	
INFORMATION DISCLOSURE STATEMENT FOR PATENT (Use several sheets if necessary)				APPLICANT: Pedro A. RECHE-GALLARDO, et al.			
				FILING DATE: November 8, 2001		GROUP: 1646 Not yet assigned	
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
pm	AA	Koich Akashi, et al., <u>Curr Opin Immunol</u> , 12(2):144-150, April 2000. "Lymphoid precursors"					
	AB	Richard Aspinall & Deborah Andrew, <u>Vaccine</u> , 18(16):1629-1637, February 25, 2000. "Thymic atrophy in the mouse is a soluble problem of the thymic environment"					
	AC	P.C.L. Beverley & B. Grubeck-Loebenstein, <u>Vaccine</u> , 18(16):1721-1724, February 25, 2000. "Is immune senescence reversible?"					
	AD	Laurel M. Bolin, et al., <u>J Neurosci</u> , 17(14):5493-5502, July 15, 1997. "HNMP-1: a novel hematopoietic and neural membrane protein differentially regulated in neural development and injury"					
	AE	Todd A. Fehniger, et al., <u>J Immunol</u> , 162(8):4511-4520, April 15, 1999. "Differential cytokine and chemokine gene expression by human NK cells following activation with IL-18 or IL-15 in combination with IL-12: implications for the innate immune response"					
	AF	Norimitsu Kadowaki, et al., <u>J Exp Med</u> , 192(2):219-226, July 17, 2000. "Natural interferon alpha/beta-producing cells link innate and adaptive immunity"					
	AG	Bradley A. Katz, <u>Biomol Eng</u> , 16(1-4):57-65, December 31, 1999. "Streptavidin-binding and -dimerizing ligands discovered by phage display, topochemistry, and structure-based design"					
	AH	Anthony D. Kelleher & Sarah L. Rowland-Jones, <u>Curr Opin Immunol</u> , 12(4):370-374, August 2000. "Functions of tetramer-stained HIV-specific CD4(+) and CD8(+) T cells"					
	AI	Toshio Kitamura, <u>Int J Hematol</u> , 67(4):351-359, June 1998. "New experimental approaches in retrovirus-mediated expression screening"					
	AJ	Bruce Koppelman, et al., <u>Immunity</u> , 7(6):861-871, December 1997. "Interleukin-10 down-regulates MHC class II alphabeta peptide complexes at the plasma membrane of monocytes by affecting arrival and recycling"					
✓	AK	Graham S. Ogg & Andres J. McMichael, <u>Curr Opin Immunol</u> , 10(4):393-396, August 1998. "HLA-peptide tetrameric complexes"					
EXAMINER Prerna Murti				DATE CONSIDERED 4/12/04			
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							




RECEIVED

DEC 20 2002

TECH CENTER 1600/2900 Sheet 2 of 2

FORM PTO-1449		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: DX01341	SERIAL NO.: 10/008,566
INFORMATION DISCLOSURE STATEMENT FOR PATENT (Use several sheets if necessary)				APPLICANT: Pedro A. RECHE-GALLARDO, et al.	
				FILING DATE: November 8, 2001	
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)					
PM	AL	Linda S. Park, et al. J Exp Med, 192(5):659-670, September 4, 2000. "Cloning of the murine thymic stromal lymphopoietin (TSLP) receptor: Formation of a functional heteromeric complex requires interleukin 7 receptor"			
	AM	Anne Puel & Warren J. Leonard, Curr Opin Immunol, 12(4):468-73, August 2000. "Mutations in the gene for the IL-7 receptor result in T(-)B(+)NK(+) severe combined immunodeficiency disease"			
	AN	John E. Sims. et al., J Exp Med, 192(5):671-680, September 4, 2000. "Molecular cloning and biological characterization of a novel murine lymphoid growth factor"			
	AO	Angela Stoddart, et al., Immunol Rev, 175:47-58, June 2000. "The role of the preBCR, the interleukin-7 receptor, and homotypic interactions during B-cell development"			
V	AP	T.A. Waldmann, Ann Oncol, 11 Suppl 1:101-106, 2000. "T-cell receptors for cytokines: targets for immunotherapy of leukemia/lymphoma"			
EXAMINER Prerna Mehta			DATE CONSIDERED 4/12/04		
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					



3 of 4

PTO/SB/08A (04/03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	10/008,566
				Filing Date	11/08/2001
				First Named Inventor	Pedro A. Reche-Gallardo
				Art Unit	1644 1646
				Examiner Name	Unknown <i>Prerna Menz</i>
Sheet	1	of	2	Attorney Docket Number	DX01341

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	DOCUMENT NUMBER	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant, Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

RECEIVED
APR 15 2003
TECH CENTER 1600/2300

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant, Passages or Relevant Figures Appear	T ⁶
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				
PM	AQ	WO 00 17362 A	03/30/2000	Schering Corporation		
PM	AR	WO 99 47538 A	09/23/1999	Human Genome Sciences Inc.; ROSEN, Craig A.; MOORE, Paul A.		

Examiner Signature	<i>Prerna Menz</i>	Date Considered	4/12/04
--------------------	--------------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.¹ Applicant's unique citation designation number (optional).² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04.³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible.⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

Application Number	10/008,566
--------------------	------------

Filing Date	11/08/2001
--------------------	------------

First Named Inventor **Pedro A. Reche-Gallardo**

Art Unit	1644	1646
----------	------	------

Examiner Name	Unknown Prema Menz
---------------	-------------------------------

Attorney Docket Number | **DX01341**

NON PATENT LITERATURE DOCUMENTS

Examiner
Initials*

Cite
No. 1

Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.

T

PM

AS

PANDEY, A. et al., "Cloning of a receptor subunit required for signaling by thymic stromal lymphopoietin", NATURE IMMUNOLOGY, UNITED STATES JUL 2000, vol. 1, no. 1, July 2000 (2000-07), pages 59-64, XP008014551, ISSN 1529-2908, abstract: figures 1,4,5,7.

AT

LEVIN, S. D. et al., "Thymic stromal lymphopoietin (TSLP): A cytokine that promotes the development of IgM+ B cells in vitro and signals via a novel mechanism", FASEB JOURNAL, vol. 13, no. 4, Part 1, 12 March 1999, page A322, XP008014578, Annual Meeting of the Professional Research Scientists for Experimental Biology 99, Washington DC, USA, April 17-21, 1999, ISSN 0892-6638, the whole document.

RECEIVED
APR 15 2003
TECH CENTER 1600/2900

**Examiner
Signature**

Perna Ment

Date
Considered

4/12/04

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.